NEW YORK, Nov. 30, 2010 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, recently received its Central Contractor Registration (CCR) from the U.S. Government. The registration qualifies Regenicin to receive funding from the Federal Government through contracts, grants, cooperative agreements and other forms of federal assistance.
The Central Contractor Registration is the primary registrant database for the U.S. Federal Government. A CCR registration is required prior to being awarded a contract with any federal government agency. The CCR also serves as a search engine for contracting officers and a link to current procurement opportunities.
“Obtaining our CCR makes us eligible to apply for Federal Grants that could support Regenicin in the development and commercialization of current and future therapeutic candidates,” says Chris Hadsall, COO for Regenicin. “This is an important milestone since the government has already provided, and is expected to continue to provide millions of dollars in grants to advancements in regenerative medicine.”
About Regenicin
Regenicin, Inc. (www.regenicin.com) is a development stage biotechnology company. Regenicin is a publicly traded company, with headquarters in New York. Additional information can be found in the company’s filings with the Securities and Exchange Commission located at www.sec.gov.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Regenicin, Inc.
